Barclays
SIOX

Barclays’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Barclays’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,675
Closed -$2.18M – 7194
2017
Q3 		$2.18M Buy
39,675
+31,487
+385% +$5.31M ﹤0.01% 2252
2017
Q2 		$1.52M Buy
8,188
+1,938
+31% +$340K ﹤0.01% 2499
2017
Q1 		$747K Buy
+6,250
New +$655K ﹤0.01% 3012

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's SIOX Position: Q1 2020 in Review

Barclays sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 144 shares — an estimated $1K sold.

Barclays first reported a position in SIOX in Q3 2016 and held it in 13 quarters. The position peaked at $1.94M in Q2 2017. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

  • Barclays reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 144 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $1K.
  • Barclays first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2016 and held it in 13 quarters.
  • Barclays's Sio Gene Therapies Inc. Common Stock position peaked at $1.94M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.